Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

Recruiting now

Conditions studied: Newly Diagnosed Multiple Myeloma (NDMM)

In brief

To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China. Leveraging the extensive patient resources of China's large center for blood disorders, the investigator will recruit approximately 500 NDMM patients to establish an NDMM patient cohort. The investigator will collect data on disease characteristics, treatment patterns, and clinical outcomes through one year of clinical follow-up. Further long-term follow-up is needed to obtain survival status and causes of death, so as to provide essential evidence for optimizing and improving patients' prognosis in clinical individualized treatment.

Key facts

Study ID

NCT07296627

Run by

Peking University People's Hospital

People needed

500

Starts

2025-07-16

Expected to finish

2027-11-15

Last updated by the study team

2025-12-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed multiple myeloma (NDMM)
• Plan to receive first-line immunotherapy at the respective research center
• First-line immunotherapy includes proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), or anti-CD38 monoclonal antibodies, used alone or in combination with each other or with other treatments
• Age ≥ 18 years
• Ability to understand the purpose of the study and follow-up process
• Willingness to provide signed and dated written informed consent

You may not qualify if…

• Patients who did not receive any follow-up after initial diagnosis

Where it is running

• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.